Radiotherapy in the Treatment of Primary Central Nervous System Lymphoma (PCNSL)

被引:0
作者
Diana Furst Nelson
机构
[1] Mayo Clinic,Radiation Oncology
来源
Journal of Neuro-Oncology | 1999年 / 43卷
关键词
non-Hodgkin's lymphoma of brain; brain lymphoma; radiotherapy; combined modality therapy;
D O I
暂无
中图分类号
学科分类号
摘要
The use of radiotherapy alone to treat primary central nervous system lymphoma (PCNSL) does not produce the high local control and survival rates that it does in limited extranodal non-Hodgkin's lymphoma outside the central nervous system (CNS). Even with doses of whole brain radiation therapy (WBRT) to 40+20 Gy boost, the Radiation Therapy Oncology Group (RTOG) reported a local control rate of 39%. Seventy-nine percent of recurrences were in the 60 Gy region. The median survival was 11.6 months. This response to local radiotherapy is quite different from the response of non-CNS Diffuse Large Cell Lymphoma where doses of 30–40 and >40 Gy have a 75–90% local control rate. Neither systemic lymphoma nor PCNSL have a classic radiotherapy dose response. For PCNSL there appears to be a threshold dose that ranges in the literature between 30 and ≥50 Gy with a median of 40 Gy. Therefore, when radiotherapy is combined with chemotherapy that crosses the BBB, WBRT and/or boost doses may be able to be decreased, especially in patients achieving a complete response. Promising data from the Centre Leon Berard suggest that this is possible. When such chemotherapy was combined with intrathecal chemotherapy and 20 Gy WBRT, they obtained a 56% actuarial 5 year survival rate. Confirmation of single institution reports of favorable results such as these are needed. Cooperative group and intergroup trials are needed to define optimal therapy.
引用
收藏
页码:241 / 247
页数:6
相关论文
共 175 条
  • [1] Eby NL(1988)Increasing incidence of primary brain lymphoma in the U.S Cancer 62 2461-2465
  • [2] Grufferman S(1992)Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315 Int J Radiat Oncol Biol Phys 23 9-17
  • [3] Flannelly CM(1996)Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group Protocol 88–06 J Clin Oncol 14 556-564
  • [4] Schold SC(1995)Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int Radiat Oncol Biol Phys 33 663-673
  • [5] Vogel FS(1994)Primary central nervous system lymphoma in Japan: a retrospective, cooperative study by CNSLymphoma Study Group in Japan J Neuro-Oncol 19 197-215
  • [6] Burger PC(1994)Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome J Neurosurg 81 188-195
  • [7] Nelson DF(1996)Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy J Clin Oncol 14 945-954
  • [8] Martz KL(1989)Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma Cancer 63 939-947
  • [9] Bonner H(1974)Primary malignant lymphomas of the central nervous system Cancer 34 1293-2052
  • [10] Nelson JS(1983)Primary non-Hodgkin's lymphoma of the central nervous system. Results of radiotherapy in 15 cases Cancer 51 2048-252